Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone617-679-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.45 billion
Profitability
Miscellaneous
Employees7,800
Next Earnings Date10/22/2019 (Confirmed)
OptionableOptionable
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) released its quarterly earnings data on Tuesday, July, 23rd. The biotechnology company reported $9.15 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $7.58 by $1.57. The biotechnology company had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.48 billion. Biogen had a net margin of 37.62% and a return on equity of 44.89%. The business's revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.80 earnings per share. View Biogen's Earnings History.
When is Biogen's next earnings date?
How can I listen to Biogen's earnings call?
Biogen will be holding an earnings conference call on Tuesday, October 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Biogen issued on next quarter's earnings?
Biogen updated its FY19 earnings guidance on Tuesday, July, 23rd. The company provided EPS guidance of $31.50-32.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $29.76. The company issued revenue guidance of $14-14.2 billion, compared to the consensus revenue estimate of $13.96 billion.
What price target have analysts set for BIIB?
30 equities research analysts have issued 12-month price targets for Biogen's stock. Their predictions range from $198.00 to $400.00. On average, they anticipate Biogen's share price to reach $267.17 in the next year. This suggests a possible upside of 18.2% from the stock's current price. View Analyst Price Targets for Biogen.
What is the consensus analysts' recommendation for Biogen?
30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 22 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Cantor Fitzgerald analysts commented, ": Reiterate Neutral rating and $250 price target. Yesterday Novartis (NVS, NC) announced FDA approval of its oral S1P1 Mayzent (siponimod) in secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome using a priority voucher. We think this broad label is somewhat unexpected given that the pivotal study and regulatory filings were for SPMS patients, and a negative headline for competitors such as Biogen and possibly Celgene CELG, OW). With competitive efficacy and a cleaner label vs. NVS’ first gen S1P1 Gilenya, we think the key question is if and how quickly Mayzent can take share in RRMS post launch in early 2Q." (3/27/2019)
- 2. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)
Has Biogen been receiving favorable news coverage?
News headlines about BIIB stock have trended very negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Biogen.
Are investors shorting Biogen?
Biogen saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 3,470,000 shares, a decrease of 8.7% from the August 15th total of 3,800,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is currently 2.4 days. Currently, 1.9% of the company's stock are sold short. View Biogen's Current Options Chain.
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE) and Adaptive Biotechnologies (ADPT).
What other stocks do shareholders of Biogen own?
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 57)
- Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
- Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
- Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)
Who are Biogen's major shareholders?
Biogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.37%), Gateway Investment Advisers LLC (0.07%), Country Trust Bank (0.06%), Hexavest Inc. (0.05%), Artemis Investment Management LLP (0.05%) and DNB Asset Management AS (0.04%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Country Trust Bank, Ingalls & Snyder LLC, CIBC Private Wealth Group LLC, Ipswich Investment Management Co. Inc., Lau Associates LLC, Bowling Portfolio Management LLC and Crossmark Global Holdings Inc.. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., DNB Asset Management AS, Cim LLC, Denali Advisors LLC, State of Alaska Department of Revenue, Artemis Investment Management LLP, Clarus Wealth Advisors and Winmill & CO. Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $226.06.
How big of a company is Biogen?
Biogen has a market capitalization of $41.70 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.View Additional Information About Biogen.
What is Biogen's official website?
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]
MarketBeat Community Rating for Biogen (NASDAQ BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
